(Total Views: 135)
Posted On: 03/16/2017 8:07:43 AM
Post# of 72443
News
Cellceutix’s Phase 2 Drug Candidate Brilacidin Emerging as a Potential Novel Non-Biologic Therapy in Treating Inflammatory Bowel Disease
Brilacidin
Study to help guide Cellceutix in continued development of Brilacidin, including planned foam and oral formulations for hard-to-treat chronic conditions like Ulcerative Colitis and Crohn’s Disease
http://www.cellceutix.com/press-release/2017/...el-disease
So, how many get frustrated when a company says, "hey! News is coming next week!"
Just report the news already! When it happens! Geesh.
Cellceutix’s Phase 2 Drug Candidate Brilacidin Emerging as a Potential Novel Non-Biologic Therapy in Treating Inflammatory Bowel Disease
Brilacidin
Study to help guide Cellceutix in continued development of Brilacidin, including planned foam and oral formulations for hard-to-treat chronic conditions like Ulcerative Colitis and Crohn’s Disease
http://www.cellceutix.com/press-release/2017/...el-disease
So, how many get frustrated when a company says, "hey! News is coming next week!"
Just report the news already! When it happens! Geesh.
(2)
(0)Scroll down for more posts ▼
